Polish Journal of Pathology
eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
2/2025
vol. 76
 
Share:
Send email
Share:
Original paper

FOXC1 expression profile in invasive breast carcinomas and its relationship with prognostic parameters

Özge Bozkurt Öztürk
1
,
Remzi Arslan
1

  1. Department of Pathology, Atatürk University Faculty of Medicine, Erzurum, Turkey
Pol J Pathol 2025; 76 (2): 79-86
DOI: https://doi.org/10.5114/pjp.2025.153969
Online publish date: 2025/09/22
Article file
- PJP-03297.pdf  [1.92 MB]
Get citation
 
PlumX metrics:
 
1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-E86.
2. Kumar V, Abbas AK, Aster JC. Robbins Basic Pathology. 10th ed. Elsevier, Philadephia 2018.
3. American Cancer Society. Cancer Facts & Figures 2023. Avail­able at: https://www.cancer.org/content/dam/cancer-org/re­search/cancer-facts-and-statistics/annual-cancer-facts-and-fig­ures/2023/2023-cancer-facts-and-figures.pdf (Access: May 27, 2025).
4. International Agency for Research on Cancer. WHO Classifi­cation of Tumours: Breast Tumours. 5th ed. IARC 2019.
5. Szylberg Ł, Antoniewicz E, Olszewski W, et al. PD-L1 expres­sion in triple-negative breast cancer: a cross-sectional study in a Polish population. Pol J Pathol 2020; 71: 301-306.
6. McDonald ES, Clark AS, Tchou J, Zhang P, Freedman GM. Clinical diagnosis and management of breast cancer. J Nucl Med 2016; 57(Suppl 1): 9S-16S.
7. Elian FA, Yan E, Walter MA. FOXC1, the new player in the cancer sandbox. Oncotarget 2018; 9: 8165.
8. Han B, Bhowmick N, Qu Y, Chung S, Giuliano AE, Cui X. FOXC1: an emerging marker and therapeutic target for can­cer. Oncogene 2017; 36: 3957-3963.
9. Yang Z, Jiang S, Cheng Y, et al. FOXC1 in cancer development and therapy: deciphering its emerging and divergent roles. Ther Adv Med Oncol 2017; 9: 797-816.
10. Li M, Lv H, Zhong S, Zhou S, Lu H, Yang W. FOXC1: a spe­cific biomarker for triple-negative breast cancer diagnosis and classification. Arch Pathol Lab Med 2022; 146: 994-1003.
11. Ray PS, Bagaria SP, Wang J, et al. Basal-like breast cancer de­fined by FOXC1 expression offers superior prognostic value: a retrospective immunohistochemical study. Ann Surg Oncol 2011; 18: 3839-3847.
12. Xia L, Huang W, Tian D, et al. Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Hepatology 2013; 57: 610-624.
13. Wei LX, Zhou RS, Xu HF, Wang JY, Yuan MH. High ex­pression of FOXC1 is associated with poor clinical outcome in non-small cell lung cancer patients. Tumour Biol 2013; 34: 941-946.
14. Xu YY, Tian J, Hao Q, Yin LR. MicroRNA-495 downregulates FOXC1 expression to suppress cell growth and migration in endometrial cancer. Tumour Biol 2016; 37: 239-251.
15. Provenzano E, Ulaner GA, Chin SF. Molecular classification of breast cancer. PET Clin 2018; 13: 325-338.
16. Ou-Yang L, Xiao SJ, Liu P, et al. Forkhead box C1 induces ep­ithelial-mesenchymal transition and is a potential therapeutic target in nasopharyngeal carcinoma. Mol Med Rep 2015; 12: 8003-8009.
17. Wang J, Xu Y, Li L, et al. FOXC1 is associated with estrogen receptor alpha and affects sensitivity of tamoxifen treatment in breast cancer. Cancer Med 2017; 6: 275-287.
18. Muggerud AA, Rønneberg JA, Wärnberg F, et al. Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res 2010; 12: 1-10.
19. Ray PS, Wang J, Qu Y, et al. FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast can­cer. Cancer Res 2010; 70: 3870-3976.
20. Johnson J, Choi M, Dadmanesh F, et al. FOXC1 identifies bas­al-like breast cancer in a hereditary breast cancer cohort. On­cotarget 2016; 7: 75729.
21. Logan L Uchic-Boccella J, Clark B, et al. 196 FOXC1 Ex­pression in Triple Negative Breast Cancers Correlates with Non-Apocrine Histology and Other Basal Marker Reactivity. Laboratory Investigation 2025; 105.3.
22. Li M, Zhou S, Lv H, et al. FOXC1 and SOX10 in Estrogen Receptor–Low Positive/HER2-Negative Breast Cancer: Poten­tial Biomarkers for the Basal-like Phenotype Prediction. Arch Pathol Lab Med 2024; 148: 461-70.
23. Hu H, Tong K, Tsang J, et al. Subtyping of triple-negative breast cancers: its prognostication and implications in diagno­sis of breast origin. ESMO Open 2024; 9: 102993.
24. Sizemore ST, Keri RA. The forkhead box transcription factor FOXC1 promotes breast cancer invasion by inducing matrix metalloprotease 7 (MMP7) expression. J Biol Chem 2012; 287: 24631-24640.
25. Li M, Zhou S, Lv H, Cai M, Shui R, Yang W. Neoadjuvant che­motherapy response in androgen receptor-positive triple-nega­tive breast cancer: potential predictive biomarkers and genetic alterations. Breast Cancer Res 2025; 27: 1-14.
26. Xu Y, Shao QS, Yao HB, Jin Y, Ma YY, Jia LH. Overexpression of FOXC1 correlates with poor prognosis in gastric cancer pa­tients. Histopathology 2014; 64: 963-970.
27. Subramani R, Camacho FA, Levin CI, et al. FOXC1 plays a crucial role in the growth of pancreatic cancer. Oncogenesis 2018; 7: 52.
28. Kume T, Shackour T. Meta-analysis of the likelihood of FOXC1 expression in early- and late-stage tumors. Oncotarget 2018; 9: 36625.
29. Zhang Y, Liao Y, Chen C, et al. p38‐regulated FOXC1 stability is required for colorectal cancer metastasis. J Pathol 2020; 250: 217-230.
Copyright: © 2025 Polish Association of Pathologists and the Polish Branch of the International Academy of Pathology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.